Literature DB >> 10371492

Is an HIV vaccine possible?

A J McMichael, T Hanke.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10371492     DOI： 10.1038/9455

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Construction of an artificial immunogen, a candidate DNA vaccine encoding multiple CTL epitopes of HIV-1.

Authors:  S I Bazhan; P A Belavin; S V Seregin; N K Danilyuk; I N Babkina; L I Karpenko; N A Nekrasova; L R Lebedev; A P Agafonov; G M Ignat'ev; A A Il'ichev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

3.  Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.

Authors:  H V Nielsen; S L Lauemøller; L Christiansen; S Buus; A Fomsgaard; E Petersen
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Authors:  Penny L Moore; Emma T Crooks; Lauren Porter; Ping Zhu; Charmagne S Cayanan; Henry Grise; Paul Corcoran; Michael B Zwick; Michael Franti; Lynn Morris; Kenneth H Roux; Dennis R Burton; James M Binley
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 5.  Immunotherapy of cancer in 2012.

Authors:  John M Kirkwood; Lisa H Butterfield; Ahmad A Tarhini; Hassane Zarour; Pawel Kalinski; Soldano Ferrone
Journal:  CA Cancer J Clin       Date:  2012-05-10       Impact factor: 508.702

Review 6.  HIV-1 prophylactic vaccines: state of the art.

Authors:  Jean-Daniel Lelièvre; Yves Lévy
Journal:  J Virus Erad       Date:  2016-01-01

7.  Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.

Authors:  Yves Lévy; Christine Lacabaratz; Kim Ellefsen-Lavoie; Wolfgang Stöhr; Jean-Daniel Lelièvre; Pierre-Alexandre Bart; Odile Launay; Jonathan Weber; Bernd Salzberger; Aurélie Wiedemann; Mathieu Surenaud; David M Koelle; Hans Wolf; Ralf Wagner; Véronique Rieux; David C Montefiori; Nicole L Yates; Georgia D Tomaras; Raphael Gottardo; Bryan Mayer; Song Ding; Rodolphe Thiébaut; Sheena McCormack; Geneviève Chêne; Giuseppe Pantaleo
Journal:  PLoS Pathog       Date:  2020-06-26       Impact factor: 6.823
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.